Dexamethasone De-Escalation in Neoadjuvant Chemoimmunotherapy for Triple-Negative Breast Cancer
NCT07914309 is a phase 2 interventional trial sponsored by Washington University School of Medicine. As of 21 Nov 2026, it is not yet recruiting. It studies Carboplatin, Cyclophosphamide, Dexamethasone, Diphenhydramine and 5 more drugs in Breast Cancer, Triple Negative Breast Cancer and 1 more condition. The registry lists an enrollment of 17 participants at 2 sites in 1 country. The registry lists a start date of 30 Nov 2026 and a primary completion date of 8 Feb 2028. One of its registered investigators has a FindMyKOL profile.
Key facts
Registry attributes as recorded on the ClinicalTrials.gov study record.
| Field | Value |
|---|---|
| Registry ID | NCT07914309 |
| Status | Not yet recruiting |
| Phase | Phase 2 |
| Study type | Interventional trial |
| Lead sponsor | Washington University School of Medicine |
| Enrollment | 17 |
| Registered sites | 2 |
| Countries | 1 |
| Conditions | Breast Cancer, Triple Negative Breast Cancer and Triple Negative Breast Cancer (TNBC) |
| Drugs | Carboplatin, Cyclophosphamide, Dexamethasone, Diphenhydramine, Doxorubicin, Famotidine, Olanzapine, Paclitaxel and Pembrolizumab |
| Start | 30 Nov 2026 |
| Primary completion | 8 Feb 2028 |
| Study completion | 31 May 2033 |
| Last update posted | 3 Nov 2026 |
Registered summary
The lay summary the sponsor registered on ClinicalTrials.gov.
Investigators
The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.
- Faisal Fa'ak, MD
Washington University School of Medicine
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
2 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- St. Luke's Hospital
Kansas City
Timothy Pluard, MDWhitney Hensing, MD - Washington University School of Medicine
St Louis
Alaina Kessler, MD, MPHAndrew Davis, MDAshley Frith, MDBisi Ademuyiwa, MD, MPH, MSCICynthia Ma, MD, PhDEmily Podany, MDFaisal Fa'ak, MDJingqin (Rosy) Luo, PhDKatherine Clifton, MDMara Hofherr, PharmDNusayba Bagegni, MDRon Bose, MD, PhD
United States, by state
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Questions about NCT07914309
Each answer restates registry values shown on this page.
What is NCT07914309?
NCT07914309 is a phase 2 interventional trial sponsored by Washington University School of Medicine. It studies Carboplatin, Cyclophosphamide, Dexamethasone, Diphenhydramine and 5 more drugs in Breast Cancer, Triple Negative Breast Cancer and 1 more condition.
Is NCT07914309 recruiting?
As of 21 Nov 2026, it is not yet recruiting.
Who leads NCT07914309?
The registry names Faisal Fa'ak, MD (principal investigator, Washington University School of Medicine) as the overall official.
Where does NCT07914309 run?
The registry lists 2 sites in 1 country. Every site with a stated country is in one country: United States.
Which drugs does NCT07914309 study?
The registered drug and biological interventions are Carboplatin, Cyclophosphamide, Dexamethasone, Diphenhydramine, Doxorubicin, Famotidine, Olanzapine, Paclitaxel and Pembrolizumab.
When is NCT07914309 expected to complete?
The registry lists a primary completion date of 8 Feb 2028 and a study completion date of 31 May 2033. The sponsor last updated the record on 3 Nov 2026.
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 21 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.